limited experience colostrum seems to be superior. On the basis of these findings we suggest a potential benefit of colostrum for severe gut GVHD. noted, her clinical course was complicated by the development of chronic graft-versus-host disease as well as generalized myasthenia gravis treated successfully with corticosteroids, pyridostigmine and thymectomy. In March 1997, 37 months after the initial diagnosis of myasthenia gravis, the patient presented to a peripheral hospital with progressive dysphagia, dysphonia, ptosis and shoulder and pelvic girdle weakness. These symptoms occurred while tapering prednisone to 5 mg/day. The patient did not improve with prednisone 40 mg/day and reinstitution of pyridostigmine. Despite hospitalization and high-dose corticosteroids, she experienced a myasthenic crisis with respiratory arrest, necessitating ICU admission, prolonged mechanical ventilation, tracheostomy and percutaneous enterojejunostomy. She suffered severe hypoxic encephalopathy; her subsequent clinical course was complicated by recurrent aspiration pneumonia, acute gastrointestinal bleeding and urosepsis. She has remained in an acute care hospital for the past 10 months.
M Inoue
Although it is a rare complication of allogeneic bone marrow transplantation, myasthenia gravis is of considerable significance. Of the 11 cases reported in the literature, there have been four life-threatening or fatal complications related to the disease or its treatment. As this case illustrates, the outcome of this disease can be devastating.
Successfully treated invasive central nervous system aspergillosis in an allogeneic stem cell transplant recipient
In the July (2) 1997 issue of Bone Marrow Transplantation, Khoury and colleagues 1 report an allogeneic transplant recipient who was treated for central nervous system aspergillosis. We wish to report our experience with a patient who underwent BMT in our unit and survived invasive aspergillosis of the CNS. An 18-year-old female was diagnosed with very severe aplastic anemia, with pancytopenia (Hb: 7 g/dl, WBC: 1.8 × 10 9 /l, Plt: 9 × 10 9 /l and ANC: 0) and a hypocellular (10% cellularity) bone marrow. She had a fully HLAmatched sister and proceeded to allogeneic BMT. She was febrile and receiving imipenem-cilastatin and vancomycin when she started the conditioning regimen, consisting of ATG 30 mg/kg/day on days −4 to −2 and CY 50 mg/kg once daily i.v. on days −5 to −2. Fluconazole was added and she was afebrile on day −1. On the same day a repeat X-ray examination of the thorax revealed an infiltrate in the lower segment of the right upper lobe; ceftazidime was changed for imipenem. Sixteen days later she was again febrile and the pulmonary infiltrate was found to be progressing, so therapy was changed to liposomal amphotericin B (AmBisome, Nexstar, San Dimas, CA, USA) 1 mg/kg/day and the former antimicrobials were withheld; G-CSF 5 g/kg/day, s.c. was added. After 2 days of this treatment she became afebrile. On day +32 (10 days later) she began to complain of a frontal headache for which no cause was apparent but a CT scan of the cranium showed the presence of a wellcircumscribed round lesion in the right frontal lobe, causing 
